|
ИСТИНА |
Войти в систему Регистрация |
ИПМех РАН |
||
Conventional white light imaging-assisted transurethral resection of bladder tumour (TURBT) versus IMAGE1S-assisted TURBT in non-muscle-invasive bladder cancer patients: trial protocol and 18 months resultsстатья
Статья опубликована в высокорейтинговом журнале
Информация о цитировании статьи получена из
Scopus
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 29 июня 2022 г.
- Авторы: de la Rosette Jean, Martov Alexey, Hurle Rodolfo, Favre Gabriel, Mamoulakis Charalampos, de Oliveira Manuel Castanheira, Stenz Arnulf, Linares-Espinós Estefania, Trelles Guzman Carlos R., Gravas Stavros, Knoll Thomas, Boz Mustafa Yucel, Herrmann Thomas, Laguna Pilar
- Журнал: World Journal of Urology
- Том: 40
- Год издания: 2022
- Издательство: Springer Verlag
- Местоположение издательства: Germany
- Первая страница: 727
- Последняя страница: 738
- DOI: 10.1007/s00345-021-03866-4
- Аннотация: PurposeWhite light (WL) is the traditional imaging modality for transurethral resection of bladder tumour (TURBT). IMAGE1S is a likely addition. We compare 18-mo recurrence rates following TURBT using IMAGE1S versus WL guidance.MethodsTwelve international centers conducted a single-blinded randomized controlled trial. Patients with primary and recurrent non-muscle-invasive bladder cancer (NMIBC) were randomly assigned 1:1 to TURBT guided by IMAGE1S or WL. Eighteen-month recurrence rates and subanalysis for primary/recurrent and risk groups were planned and compared by chi-square tests and survival analyses.Results689 patients were randomized for WL-assisted (n = 354) or IMAGE1S-assisted (n = 335) TURBT. Of these, 64.7% had a primary tumor, 35.3% a recurrent tumor, and 4.8%, 69.2% and 26.0% a low-, intermediate-, and high-risk tumor, respectively. Overall, 60 and 65 patients, respectively, completed 18-mo follow-up, with recurrence rates of 31.0% and 25.4%, respectively (p = 0.199). In patients with primary, low-/intermediate-risk tumors, recurrence rates at 18-mo were significantly higher in the WL group compared with the IMAGE1S group (31.9% and 22.3%, respectively: p 0.035). Frequency and severity of adverse events were comparable in both treatment groups. Immediate and adjuvant intravesical instillation therapy did not differ between the groups. Potential limitations included lack of uniformity of surgical resection, central pathology review, and missing data.ConclusionThere was not difference in the overall recurrence rates between IMAGE1S and WL assistance 18-mo after TURBT in patients with NMIBC. However, IMAGE1S-assisted TURBT considerably reduced the likelihood of disease recurrence in primary, low/intermediate risk patients.
- Добавил в систему: Мартов Алексей Георгиевич